BurtRKBalabanovRBurmanJ, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. JAMA2019; 321: 165.
4.
MuraroPAZitoASignoriA, et al. Effectiveness of autologous hematopoietic stem cell transplantation versus alemtuzumab and ocrelizumab in relapsing multiple sclerosis: A single center cohort study. Ann Neurol2025; 98(2): 294–307.
5.
MuraroPAMariottiniAGrecoR, et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder—Recommendations from ECTRIMS and the EBMT. Nat Rev Neurol2025; 21(3): 140–158.
6.
BoffaGMassacesiLIngleseM, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology2021; 96: e1215–e1226.
7.
SilfverbergTZjukovskajaCLjungmanP, et al. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: An observational cohort study. J Neurol Neurosurg Psychiatry2024; 95: 125–133.
8.
HartungH-PBenedictRHBBergerT, et al. Ocrelizumab in early-stage relapsing-remitting multiple sclerosis: The phase IIIb ENSEMBLE 4-year, single-arm, open-label trial. Neurology2024; 103: e210049.
9.
SormaniMPMuraroPASchiavettiI, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. Neurology2017; 88: 2115–2122.
10.
KalincikTSharminSRoosI, et al. Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis. JAMA Neurol2023; 80: 702.
